Morning Cancer Treatment Nearly Doubles Survival Time
A groundbreaking study found that cancer patients who received immunotherapy before 3pm lived an average of 28 months, compared to just 17 months for those treated later in the day. This simple timing shift could transform cancer care worldwide.
